marketcaparena
Search

    TVRD

    Tvardi Therapeutics, Inc.

    Company overview

    Market capitalization
    $17.74M
    Employees
    12
    Latest publication
    2026-09-29
    About Tvardi Therapeutics, Inc.

    Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD0USD0USD0USD2,569,000USD1,455,000USD2,556,000USD991,000USD
    Research Development4,911,000USD5,491,000USD3,603,000USD5,806,000USD319,000USD8,603,000USD4,795,000USD6,531,000USD
    Selling General Administrative2,140,000USD2,096,000USD2,335,000USD3,063,000USD4,636,000USD2,199,000USD881,000USD650,000USD
    Total Operating Expenses7,051,000USD7,587,000USD5,938,000USD8,822,000USD4,955,000USD10,802,000USD5,676,000USD7,176,000USD
    Operating Income-7,051,000USD-7,587,000USD-5,938,000USD-8,869,000USD-2,386,000USD-10,802,000USD-5,676,000USD-7,181,000USD
    Interest Income247,000USD312,000USD411,000USD377,000USD275,000USD132,000USD163,000USD206,000USD
    Net Interest Income247,000USD312,000USD411,000USD377,000USD-2,867,000USD132,000USD163,000USD206,000USD
    Income Before Tax-6,804,000USD-7,275,000USD-5,527,000USD4,167,000USD-4,906,000USD-12,707,000USD-5,513,000USD-6,975,000USD
    Net Income-6,804,000USD-7,275,000USD-5,527,000USD4,167,000USD-4,906,000USD-12,707,000USD-5,513,000USD-6,975,000USD
    Net Income From Continuing Ops-6,804,000USD-7,275,000USD-5,527,000USD4,167,000USD-4,906,000USD-12,707,000USD-5,513,000USD-6,975,000USD
    Ebitda-7,051,000USD-7,563,000USD-5,527,000USD-8,822,000USD-2,039,000USD-10,778,000USD-5,652,000USD-6,970,000USD
    Reconciled Depreciation24,000USD24,000USD24,000USD47,000USD24,000USD24,000USD24,000USD5,000USD
    Total Other Income Expense Net247,000USD312,000USD411,000USD13,036,000USD-2,520,000USD-1,905,000USD163,000USD206,000USD
    Ebit—-7,587,000USD—-8,869,000USD-2,386,000USD-10,802,000USD-5,676,000USD-6,975,000USD
    Depreciation And Amortization—24,000USD—47,000USD—24,000USD24,000USD5,000USD
    Cost Of Revenue———47,000USD0USD—73,000USD5,000USD
    Gross Profit———-47,000USD2,569,000USD1,413,000USD2,483,000USD-5,000USD
    Interest Expense————2,867,000USD2,621,000USD1,960,000USD1,910,000USD
    Income Tax Expense—————-398,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Total Revenue0USD7,137,000USD20,968,000USD41,867,000USD23,028,000USD135,082,000USD
    Cost Of Revenue95,000USD812,000USD6,433,000USD7,514,000USD1,554,000USD—
    Gross Profit-95,000USD6,325,000USD14,535,000USD34,353,000USD21,474,000USD—
    Research Development18,011,000USD32,755,000USD108,381,000USD91,759,000USD82,578,000USD107,739,000USD
    Selling General Administrative8,737,000USD4,457,000USD2,799,000USD2,727,000USD——
    Total Operating Expenses26,748,000USD62,106,000USD136,030,000USD121,888,000USD110,557,000USD128,681,999USD
    Operating Income-26,748,000USD-55,781,000USD-121,495,000USD-87,535,000USD-89,083,000USD5,385,000USD
    Interest Income1,375,000USD747,000USD1,318,000USD654,000USD——
    Net Interest Income1,375,000USD747,000USD1,318,000USD651,000USD——
    Income Before Tax-18,214,000USD-71,265,000USD-118,513,000USD-85,474,000USD-88,441,000USD7,719,000USD
    Net Income-18,214,000USD-70,867,000USD-118,513,000USD-85,474,000USD-88,441,000USD8,410,000USD
    Net Income From Continuing Ops-18,214,000USD-29,397,000USD-17,347,000USD-20,542,000USD——
    Ebit-26,748,000USD-62,792,000USD-117,909,000USD-85,474,000USD-88,441,000USD7,719,001USD
    Ebitda-26,653,000USD-62,600,000USD-117,650,000USD-83,804,000USD-86,887,000USD8,734,000USD
    Depreciation And Amortization95,000USD192,000USD259,000USD1,670,000USD1,554,000USD1,014,999USD
    Reconciled Depreciation95,000USD95,000USD95,000USD85,000USD——
    Total Other Income Expense Net8,534,000USD-15,484,000USD2,982,000USD2,061,000USD642,000USD2,334,000USD
    Unclassified Operating Expenses—24,894,000USD24,850,000USD27,402,000USD27,979,000USD20,942,999USD
    Interest Expense—8,473,000USD0USD3,000USD——
    Income Tax Expense—-398,000USD———-691,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets17,517,000USD25,817,000USD32,073,000USD39,021,000USD43,750,000USD27,809,000USD43,827,000USD51,329,000USD
    Cash And Equivalents15,765,000USD———————
    Total Current Assets17,069,000USD25,326,000USD31,538,000USD38,443,000USD43,130,000USD23,458,000USD43,827,000USD47,912,000USD
    Other Current Assets1,304,000USD345,000USD727,000USD1,983,000USD2,136,000USD1,148,000USD529,000USD2,382,000USD
    Other Non Current Assets17,000USD———————
    Total Liabilities9,135,000USD———————
    Total Current Liabilities9,113,000USD11,258,000USD11,042,000USD11,040,000USD10,678,000USD6,998,000USD3,972,000USD10,039,000USD
    Other Current Liabilities4,352,000USD———————
    Total Stockholder Equity8,382,000USD14,505,000USD20,946,000USD27,866,000USD32,927,000USD-15,122,000USD-4,593,000USD707,000USD
    Total Equity Including Noncontrolling Interest8,382,000USD———————
    Property Plant Equipment Net140,000USD168,000USD196,000USD223,000USD249,000USD275,000USD300,000USD3,417,000USD
    Intangible Assets291,000USD306,000USD322,000USD338,000USD354,000USD369,000USD385,000USD401,000USD
    Accounts Payable4,638,000USD4,620,000USD3,219,000USD4,078,000USD2,425,000USD1,686,000USD1,434,000USD2,541,000USD
    Short Term Debt123,000USD120,000USD116,000USD113,000USD109,000USD106,000USD—3,417,000USD
    Common Stock9,000USD9,000USD9,000USD9,000USD9,000USD19,000USD5,000USD54,000USD
    Retained Earnings-123,711,000USD-117,254,000USD-110,450,000USD-103,175,000USD-97,648,000USD-101,815,000USD-755,612,000USD-747,933,000USD
    Total Liab—11,312,000USD11,127,000USD11,155,000USD10,823,000USD42,931,000USD48,420,000USD50,622,000USD
    Other Current Liab—6,518,000USD7,707,000USD6,849,000USD8,144,000USD5,206,000USD2,538,000USD4,081,000USD
    Capital Stock—9,000USD9,000USD9,000USD9,000USD2,000USD2,000USD19,000USD
    Good Will—306,000USD——————
    Cash—19,851,000USD20,734,000USD21,418,000USD20,648,000USD11,439,000USD37,903,000USD38,561,000USD
    Cash And Short Term Investments—24,981,000USD30,811,000USD36,460,000USD40,994,000USD22,310,000USD37,903,000USD43,536,000USD
    Net Debt—-19,677,000USD-20,533,000USD-21,190,000USD-20,394,000USD24,600,000USD6,545,000USD5,439,000USD
    Short Long Term Debt Total—174,000USD201,000USD228,000USD254,000USD36,039,000USD44,448,000USD44,000,000USD
    Short Term Investments—5,130,000USD10,077,000USD15,042,000USD20,346,000USD10,871,000USD0USD4,975,000USD
    Property Plant Equipment Gross—168,000USD196,000USD223,000USD249,000USD—300,000USD310,000USD
    Accumulated Other Comprehensive Income—1,000USD8,000USD7,000USD-13,000USD2,000USD—-25,000USD
    Common Stock Shares Outstanding—9,381,344shares9,380,819shares9,377,079shares8,455,223shares9,355,542shares1,523,742shares1,523,440shares
    Non Current Assets Total—490,999USD535,000USD578,000USD620,000USD4,351,000USD3,513,000USD3,417,000USD
    Non Current Liabilities Total—54,000USD85,000USD115,000USD145,000USD35,933,000USD44,448,000USD40,583,000USD
    Non Currrent Assets Other—16,999USD17,000USD17,000USD17,000USD3,707,000USD17,000USD1,100,000USD
    Net Working Capital—14,068,000USD20,496,000USD27,403,000USD32,452,000USD37,748,000USD21,319,000USD5,396,000USD
    Unclassified Equity—131,740,000USD131,370,000USD131,016,000USD130,570,000USD86,670,000USD751,012,000USD748,592,000USD
    Net Receivables—————2,238,000USD4,495,000USD1,369,000USD
    Inventory—————900,000USD900,000USD625,000USD
    Non Current Liabilities Other—————45,821,000USD——
    Unclassified Current Assets—————-3,138,000USD——
    Unclassified Non Current Liabilities—————-9,888,000USD14,189,000USD40,583,000USD
    Long Term Debt——————30,259,000USD—
    Unclassified Non Current Assets——————2,811,000USD-1,501,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Total Assets32,073,000USD43,827,000USD27,001,000USD45,097,000USD247,056,000USD271,157,000USD
    Intangible Assets322,000USD385,000USD448,000USD511,000USD——
    Other Current Assets727,000USD529,000USD-778,000USD-4,083,000USD2,519,000USD12,076,000USD
    Total Liab11,127,000USD48,420,000USD89,059,000USD90,148,000USD19,534,000USD22,156,000USD
    Total Stockholder Equity20,946,000USD-4,593,000USD-62,058,000USD-45,051,000USD227,522,000USD249,001,000USD
    Other Current Liab7,707,000USD2,538,000USD1,577,000USD-132,000USD10,236,000USD11,988,000USD
    Common Stock9,000USD5,000USD19,000USD19,000USD53,000USD50,000USD
    Capital Stock9,000USD2,000USD19,000USD19,000USD——
    Retained Earnings-110,450,000USD-755,612,000USD-62,839,000USD-45,492,000USD-480,758,000USD-392,317,000USD
    Cash20,734,000USD37,903,000USD22,919,000USD21,489,000USD13,453,000USD31,683,000USD
    Cash And Short Term Investments30,811,000USD37,903,000USD22,919,000USD43,739,000USD167,035,000USD180,925,000USD
    Total Current Assets31,538,000USD43,827,000USD26,158,000USD44,109,000USD173,290,000USD195,065,000USD
    Total Current Liabilities11,042,000USD3,972,000USD3,281,000USD4,277,000USD17,616,000USD18,483,000USD
    Net Debt-20,533,000USD6,545,000USD-22,551,000USD-19,121,000USD-9,780,000USD-26,408,000USD
    Short Term Debt116,000USD—93,000USD2,000,000USD1,755,000USD1,602,000USD
    Short Long Term Debt Total201,000USD44,448,000USD368,000USD2,368,000USD3,673,000USD5,275,000USD
    Short Term Investments10,077,000USD0USD48,983,000USD22,250,000USD153,582,000USD149,242,000USD
    Accounts Payable3,219,000USD1,434,000USD1,611,000USD2,409,000USD5,625,000USD4,893,000USD
    Property Plant Equipment Net196,000USD300,000USD378,000USD460,000USD3,604,000USD5,119,000USD
    Property Plant Equipment Gross196,000USD300,000USD378,000USD460,000USD——
    Accumulated Other Comprehensive Income8,000USD—-260,000USD-24,000USD-358,000USD73,000USD
    Common Stock Shares Outstanding7,783,182shares1,520,912shares9,355,542shares9,355,542shares1,408,854shares1,330,973shares
    Non Current Assets Total535,000USD3,513,000USD843,000USD988,000USD73,766,000USD76,091,999USD
    Non Current Liabilities Total85,000USD44,448,000USD85,778,000USD85,871,000USD1,917,999USD3,672,999USD
    Non Currrent Assets Other17,000USD17,000USD-1,483,000USD-11,333,000USD——
    Net Working Capital20,496,000USD21,319,000USD22,877,000USD39,832,000USD——
    Unclassified Equity131,370,000USD751,012,000USD1,003,000USD—708,585,000USD641,195,000USD
    Long Term Debt—30,259,000USD————
    Net Receivables—4,495,000USD4,017,000USD4,453,000USD1,152,000USD2,064,000USD
    Inventory—900,000USD——2,584,000USD—
    Unclassified Non Current Assets—2,811,000USD——70,162,000USD70,972,999USD
    Unclassified Non Current Liabilities—14,189,000USD85,778,000USD85,871,000USD1,917,999USD3,672,999USD
    Unclassified Current Assets——-49,761,000USD-4,083,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation47,000USD
    Stock Based Compensation705,000USD
    Deferred Income Tax0USD
    Change To Liabilities-1,937,000USD
    Change In Working Capital-2,513,000USD
    Operating Cash Flow-15,087,000USD
    Investing Cash Flow10,118,000USD
    Change In Cash-4,969,000USD
    End Cash Flow15,765,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-6,804,000USD-7,275,000USD-5,527,000USD-506,000USD-4,906,000USD-7,679,000USD-12,476,000USD-20,016,000USD
    Depreciation24,000USD24,000USD24,000USD47,000USD24,000USD24,000USD73,000USD77,000USD
    Stock Based Compensation370,000USD353,000USD339,000USD-719,000USD1,426,000USD79,000USD80,000USD-3,185,000USD
    Other Non Cash Items20,000USD-15,000USD-7,000USD-10,132,000USD94,000USD5,429,000USD8,984,000USD5,363,000USD
    Change In Working Capital566,000USD1,228,000USD914,000USD2,445,000USD-1,306,000USD-1,793,000USD-10,565,000USD2,139,000USD
    Total Cash From Operating Activities-5,859,000USD-5,685,000USD-4,257,000USD-8,865,000USD-4,692,000USD-4,043,000USD-13,984,000USD-12,437,000USD
    Capital Expenditures0USD0USD0USD0USD0USD0USD0USD-210,000USD
    Free Cash Flow-5,859,000USD-5,685,000USD-4,257,000USD-8,865,000USD-4,692,000USD-4,043,000USD-13,984,000USD-12,647,000USD
    Investments4,976,000USD5,000,000USD5,349,000USD-20,433,000USD-10,883,000USD0USD0USD-25,951,000USD
    Total Cash From Financing Activities0USD1,000USD-322,000USD22,018,000USD1,006,000USD-1,615,000USD-694,000USD-610,000USD
    Issuance Of Capital Stock0USD1,000USD107,000USD421,000USD3,000USD0USD0USD—
    Change In Cash-883,000USD-684,000USD770,000USD-13,569,000USD-3,686,000USD-658,000USD-10,678,000USD2,243,000USD
    Begin Period Cash Flow20,734,000USD21,418,000USD20,648,000USD34,217,000USD37,903,000USD38,561,000USD49,239,000USD46,996,000USD
    End Period Cash Flow19,851,000USD20,734,000USD21,418,000USD20,648,000USD34,217,000USD37,903,000USD38,561,000USD49,239,000USD
    Total Cashflows From Investing Activities—5,000,000USD5,349,000USD-20,433,000USD—5,000,000USD2,500,000USD15,290,000USD
    Other Cashflows From Financing Activities——-429,000USD22,600,000USD———-5,000USD
    Unclassified Financing Cash Flow———-1,003,000USD1,003,000USD-1,615,000USD——
    Change To Account Receivables————-822,000USD-627,000USD451,000USD1,101,000USD
    Change To Inventory————0USD-729,000USD-1,000USD-392,000USD
    Unclassified Investing Cash Flow—————5,000,000USD2,500,000USD73,664,000USD
    Other Cashflows From Investing Activities———————-32,213,000USD
    Unclassified Operating Cash Flow———————3,185,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Net Income-18,214,000USD-70,867,000USD-17,347,000USD-20,542,000USD-88,441,000USD8,410,000USD
    Depreciation95,000USD192,000USD95,000USD85,000USD1,554,000USD1,014,999USD
    Stock Based Compensation1,399,000USD319,000USD314,000USD246,000USD——
    Other Non Cash Items-7,287,000USD24,862,000USD-143,000USD-321,000USD21,537,000USD-7,544,999USD
    Change In Working Capital508,000USD-15,104,000USD-3,959,000USD2,666,000USD5,263,000USD-7,367,000USD
    Total Cash From Operating Activities-23,499,000USD-60,917,000USD-21,040,000USD-17,866,000USD-60,087,000USD-5,487,000USD
    Capital Expenditures0USD-1,046,000USD-2,375,000USD-50,000USD-39,000USD-349,000USD
    Free Cash Flow-23,499,000USD-61,963,000USD-21,040,000USD-17,916,000USD-60,126,000USD-5,836,000USD
    Investments-10,084,000USD0USD22,468,000USD-22,000,000USD——
    Total Cashflows From Investing Activities-10,084,000USD48,741,000USD22,468,000USD-22,000,000USD-4,751,000USD-20,275,000USD
    Net Borrowings0USD28,298,000USD————
    Total Cash From Financing Activities22,703,000USD-3,604,000USD2,000USD4,000USD46,608,000USD39,140,000USD
    Issuance Of Capital Stock532,000USD5,000USD2,000USD4,000USD——
    Change In Cash-10,880,000USD-14,280,000USD1,430,000USD-39,862,000USD-18,230,000USD13,378,000USD
    Begin Period Cash Flow31,614,000USD52,183,000USD21,489,000USD61,351,000USD31,683,000USD18,305,000USD
    End Period Cash Flow20,734,000USD37,903,000USD22,919,000USD21,489,000USD13,453,000USD31,683,000USD
    Other Cashflows From Financing Activities22,171,000USD—-36,474,000USD———
    Change To Account Receivables—2,021,000USD—-3,301,000USD912,000USD-277,000USD
    Change To Inventory—-1,042,000USD——-2,584,000USD—
    Unclassified Investing Cash Flow—49,787,000USD-113,605,000USD—-4,712,000USD-19,926,000USD
    Unclassified Financing Cash Flow—-31,907,000USD36,474,000USD———
    Other Cashflows From Investing Activities——115,980,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2023Quarterly · 2023-09-30ProductClinical Compound Revenue66,000USD0001558370-24-015713
    Q3 2023Quarterly · 2023-09-30ProductCollaborative Revenue2,471,000USD0001558370-24-015713
    Q3 2023Quarterly · 2023-09-30ProductCommercial Supply Revenue1,252,000USD0001558370-24-015713
    Q3 2023Quarterly · 2023-09-30ProductLicense And Milestone Fees910,000USD0001558370-24-015713
    Q3 2023Quarterly · 2023-09-30ProductOther Revenue Non Cash0USD0001558370-24-015713
    Q3 2023Quarterly · 2023-09-30ProductRoyalty167,000USD0001558370-24-015713
    Q2 2023Quarterly · 2023-06-30ProductClinical Compound Revenue0USD0001558370-24-012231
    Q2 2023Quarterly · 2023-06-30ProductCollaborative Revenue5,410,000USD0001558370-24-012231
    Q2 2023Quarterly · 2023-06-30ProductCommercial Supply Revenue1,400,000USD0001558370-24-012231
    Q2 2023Quarterly · 2023-06-30ProductOther Revenue Non Cash0USD0001558370-24-012231
    Q2 2023Quarterly · 2023-06-30ProductRoyalty123,000USD0001558370-24-012231
    Q1 2023Quarterly · 2023-03-31ProductClinical Compound Revenue99,000USD0001558370-24-007964
    Q1 2023Quarterly · 2023-03-31ProductCollaborative Revenue2,750,000USD0001558370-24-007964
    Q1 2023Quarterly · 2023-03-31ProductCommercial Supply Revenue3,191,000USD0001558370-24-007964
    Q1 2023Quarterly · 2023-03-31ProductOther Revenue Non Cash0USD0001558370-24-007964
    Q1 2023Quarterly · 2023-03-31ProductRoyalty125,000USD0001558370-24-007964
    FY 2022Yearly · 2022-12-31ProductClinical Compound Revenue0USD0001558370-25-002705
    FY 2022Yearly · 2022-12-31ProductCollaborative Revenue16,572,000USD0001558370-25-002705
    FY 2022Yearly · 2022-12-31ProductCommercial Supply Revenue10,223,000USD0001558370-25-002705
    FY 2022Yearly · 2022-12-31ProductLicense And Milestone Fees15,000,000USD0001558370-25-002705
    FY 2022Yearly · 2022-12-31ProductRoyalty72,000USD0001558370-25-002705
    Q3 2022Quarterly · 2022-09-30ProductClinical Compound Revenue0USD0001558370-23-018837
    Q3 2022Quarterly · 2022-09-30ProductCollaborative Revenue7,443,000USD0001558370-23-018837
    Q3 2022Quarterly · 2022-09-30ProductCommercial Supply Revenue3,370,000USD0001558370-23-018837
    Q3 2022Quarterly · 2022-09-30ProductLicense And Milestone Fees0USD0001558370-23-018837
    Q3 2022Quarterly · 2022-09-30ProductRoyalty0USD0001558370-23-018837
    Q2 2022Quarterly · 2022-06-30ProductClinical Compound Revenue0USD0001558370-23-013598
    Q2 2022Quarterly · 2022-06-30ProductCollaborative Revenue8,003,000USD0001558370-23-013598
    Q2 2022Quarterly · 2022-06-30ProductCommercial Supply Revenue With No Associated Costs Of Goods Sold0USD0001558370-23-013598
    Q2 2022Quarterly · 2022-06-30ProductLicense And Milestone Fees15,000,000USD0001558370-23-013598
    Q2 2022Quarterly · 2022-06-30ProductRoyalty0USD0001558370-23-013598
    Q1 2022Quarterly · 2022-03-31ProductClinical Compound Revenue0USD0001558370-23-009845
    Q1 2022Quarterly · 2022-03-31ProductCollaborative Revenue0USD0001558370-23-009845
    Q1 2022Quarterly · 2022-03-31ProductCommercial Supply Revenue4,790,000USD0001558370-23-009845
    Q1 2022Quarterly · 2022-03-31ProductRoyalty0USD0001558370-23-009845
    FY 2021Yearly · 2021-12-31ProductClinical Compound Revenue398,000USD0001558370-24-002609
    FY 2021Yearly · 2021-12-31ProductCollaborative Revenue706,000USD0001558370-24-002609
    FY 2021Yearly · 2021-12-31ProductLicense And Milestone Fees21,223,000USD0001558370-24-002609
    FY 2021Yearly · 2021-12-31ProductOther701,000USD0001558370-24-002609
    FY 2021Yearly · 2021-12-31ProductRoyalty0USD0001558370-24-002609
    Q3 2021Quarterly · 2021-09-30ProductClinical Compound Revenue241,000USD0001558370-22-016625
    Q3 2021Quarterly · 2021-09-30ProductCollaborative Revenue0USD0001558370-22-016625
    Q3 2021Quarterly · 2021-09-30ProductLicense And Milestone Fees20,031,000USD0001558370-22-016625
    Q1 2021Quarterly · 2021-03-31ProductClinical Compound Revenue37,000USD0001558370-22-007824
    Q1 2021Quarterly · 2021-03-31ProductClinical Or Commercial Compound Revenue0USD0001558370-22-007824
    Q1 2021Quarterly · 2021-03-31ProductCollaborative Revenue706,000USD0001558370-22-007824
    Q1 2021Quarterly · 2021-03-31ProductLicense And Milestone Fees1,192,000USD0001558370-22-007824
    FY 2020Yearly · 2020-12-31ProductClinical Compound Revenue643,000USD0001558370-23-002913
    FY 2020Yearly · 2020-12-31ProductCollaborative Revenue0USD0001558370-23-002913
    FY 2020Yearly · 2020-12-31ProductLicense And Milestone Fees134,439,000USD0001558370-23-002913
    FY 2019Yearly · 2019-12-31ProductClinical Compound Revenue140,000USD0001558370-22-002555
    FY 2019Yearly · 2019-12-31ProductLicense And Milestone Fees19,746,000USD0001558370-22-002555
    FY 2018Yearly · 2018-12-31ProductClinical Compound Revenue33,000USD0001558370-21-001839
    FY 2018Yearly · 2018-12-31ProductLicense And Milestone Fees13,436,000USD0001558370-21-001839
    FY 2017Yearly · 2017-12-31ProductClinical Compound Revenue68,000USD0001558370-20-001659
    FY 2017Yearly · 2017-12-31ProductLicense — Collaborative Revenue313,000USD0001558370-20-001659
    FY 2017Yearly · 2017-12-31ProductLicense And Milestone Fees530,000USD0001558370-20-001659

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.